Current Report Filing (8-k)
January 05 2021 - 04:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
January 5, 2021
Date of Report (Date of earliest event reported)

HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of Registrant as Specified in Its Charter)
DELAWARE
|
001-38445
|
36-4787690
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
642 Newtown Yardley Road, Suite 100
Newtown, PA
|
|
18940
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: (215)
944-6100
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
HSDT
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
|
|
Item 7.01
|
Regulation FD Disclosure.
|
On January 5, 2021, Helius Medical Technologies, Inc. (the
“Company”) posted an updated corporate presentation to its website
at http://heliusmedical.com/index.php/investor-relations/overview,
which the Company may use from time to time in communications or
conferences. A copy of the corporate presentation is attached as
Exhibit 99.1 to this Current Report on Form 8-K (this
“Report”).
The information in this Report, including Exhibit 99.1 hereto, is
furnished pursuant to Item 7.01 and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the
liabilities of that Section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing. The Company’s submission of
this Report shall not be deemed an admission as to the materiality
of any information required to be disclosed solely to satisfy the
requirements of Regulation FD.
This Report and Exhibit 99.1 hereto contain forward-looking
statements within the meaning of the federal securities laws. These
forward looking statements are based on current expectations and
are not guarantees of future performance. Further, the
forward-looking statements are subject to the limitations listed in
Exhibit 99.1 and in the other reports of the Company filed with the
Securities and Exchange Commission, including that actual events or
results may differ materially from those in the forward-looking
statements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
HELIUS MEDICAL TECHNOLOGIES, INC.
|
|
|
|
|
Date: January 5, 2021
|
|
By:
|
/s/ Joyce LaViscount
|
|
|
|
Joyce LaViscount
|
|
|
|
Chief Financial Officer
|
2